Dr Reddy’s sells US peni­cillin plant to Abu Dhabi-based Neopharma

Chemical Industry Digest - - News & Views -

Drug maker Dr Reddy’s Lab­o­ra­to­ries Ltd has sold its an­tibi­otic man­u­fac­tur­ing fa­cil­ity in Bris­tol, US to Abu Dhabi-based phar­ma­ceu­ti­cal man­u­fac­turer Neopharma LLC UAE. The plant and the as­so­ci­ated fa­cil­i­ties man­u­fac­tured amox­i­cillin-based prod­ucts in­clud­ing a semi-syn­thetic peni­cillin. “This sale is in line with our stated pri­or­ity to stream­line and op­ti­mize our global cost struc­tures and help us fo­cus on other busi­ness pri­or­i­ties to drive growth,” Erez Is­raeli, chief op­er­at­ing of­fi­cer at Dr Reddy’s, said in a state­ment.

With this DRL has also an­nounced the ter­mi­na­tion of its li­cence granted to Ar­mis Bio Pharma, Inc (form­ly­chd bio­science, inc) for its in­ves­ti­ga­tional an­tibac­te­rial prod­uct, DFA-02, for pro­phylxis of sur­gi­cal site in­fec­tions. Fol­low­ing this DRL has re­gained world­wide rights to DFA-02, and is cur­rently eval­u­at­ing its op­tions to take the pro­gramme for­ward.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.